Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)

NCT ID: NCT06272136

Last Updated: 2024-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-23

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-centre, multiple cohort, open study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include 5 cohorts. After each cohort, optimisation of the Spiden Clinical Demo 2.0 system and machine learning models may be pursued before the next cohort is started. Trial participants with type 1 or type 2 diabetes mellitus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Type2diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional arm

Induction of hyperglycaemia and hypoglcemia states and measurements of transcutaneous spectral data with the investigational device and reference blood glucose values measured by Super GL and Freestyle Libre 3.

Group Type EXPERIMENTAL

Clinical Demo 2.0

Intervention Type DEVICE

During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical Demo 2.0

During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female trial participant with clinically diagnosed type 1 or type 2 diabetes for at least 1 year.
* Age between 18 and 65 years, both inclusive.
* Treated with insulin and/or oral antidiabetic drugs (OADs; type 2 only), multiple dosing insulin therapy (MDI), continuous subcutaneous insulin infusion (CSII) or a hybrid closed loop system.

Exclusion Criteria

* Known or suspected hypersensitivity to any of the components of the Liom Clinical Demo 2.0.
* Trial participant with any injury, infection, atypical skin condition (e.g., hyperkeratosis, hyperpigmentation) of or tattoo on the wrists.
* Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

Sponsor Role collaborator

Liom Health AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Stoffel, MD

Role: PRINCIPAL_INVESTIGATOR

Profil for Stoffwechselforschung GmbH, Neuss, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Profil for Stoffwechselforschung GmbH

Neuss, Nordrhein-Westfallen, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Banu Eyueboglu Seitz, PhD

Role: CONTACT

0041 41 552 00 59

Fabien Rebeaud, PhD

Role: CONTACT

0041 41 552 00 59

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marc Stoffel, MD

Role: primary

0049213140180

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPN-007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GLUCOME USABILITY STUDY
NCT02488278 WITHDRAWN NA
CGM Accuracy in Pregnancy Study
NCT07269015 NOT_YET_RECRUITING NA